Maverick Capital’s Beam Therapeutics BEAM Stock Holding History

Maverick Capital’s Portfolio BEAM Stock Details BEAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-678	Closed	-$54K	–	682
2021 Q1	$54K	Buy	+678	New	+$64.5K	﹤0.01%	643

Other funds holding BEAM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Maverick Capital's BEAM Position: Q2 2021 in Review

Maverick Capital sold out of Beam Therapeutics (BEAM) in Q2 2021, closing a stake of 678 shares — an estimated $54K sold.

Maverick Capital first reported a position in BEAM in Q1 2021 and held it in 1 quarter. The position peaked at $54K in Q1 2021. 231 funds tracked by Wall St. Rank hold BEAM as of Q2 2021.

Maverick Capital reported no remaining Beam Therapeutics position as of Q2 2021 after selling out during the quarter.
Maverick Capital sold 678 Beam Therapeutics shares in Q2 2021, an estimated $54K.
Maverick Capital first reported a position in Beam Therapeutics in Q1 2021 and held it in 1 quarter.
Maverick Capital's Beam Therapeutics position peaked at $54K in Q1 2021.
231 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2021.

Based on Maverick Capital's 13F filing for Q2 2021, filed 16 Aug 2021.